{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T05:00:19Z","timestamp":1748667619972},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Psoriasis is the most common chronic inflammatory condition involving the T helper cell system. Population studies have demonstrated that patients with psoriasis and\/or psoriatic arthritis have an increased risk of developing vascular risk factors, including diabetes, hypertension, and obesity, and increased risk of adverse vascular events, including myocardial infarction and stroke. Population studies have generally investigated the individual contributions of psoriasis and psoriatic arthritis to development of vascular risk factors; fewer studies have investigated the additive contribution of comorbid inflammatory disorders. We present a case of a woman with psoriasis, psoriatic arthritis, and comorbid vascular risk factors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 49\u2009year-old Caucasian woman with a history of severe psoriasis and psoriatic arthritis since adolescence presented with bilateral lower extremity weakness. She was found to have acute bilateral watershed infarcts and multifocal subacute infarcts. Her evaluation revealed vascular risk factors and elevated non-specific systemic inflammatory markers; serum and cerebral spinal fluid did not reveal underlying infection, hypercoagulable state, or vasculitis. Over the course of days, she exhibited precipitous clinical deterioration related to multiple large vessel occlusions, including the bilateral anterior cerebral arteries and the left middle cerebral artery. Autopsy revealed acute thrombi and diffuse, severe atherosclerosis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Patients with early onset inflammatory disease activity or comorbid inflammatory disorders may have an even higher risk of developing metabolic syndrome and adverse vascular events compared to patients with late-onset disease activity or with a single inflammatory condition. The described case illustrates the complex relationship between inflammatory disorders and vascular risk factors. The degree of systemic inflammation, as measured by severity of disease activity, has been shown to have a dose-response relationship with comorbid vascular risk factors and vascular events. Dysregulation of the Th1 and Th17 system has been implicated in the development of atherosclerosis and may explain the severe atherosclerosis seen in such chronic inflammatory conditions. Further research will help refine screening and management guidelines to account for comorbid inflammatory disorders and related disease severity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-020-01681-9","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T12:02:28Z","timestamp":1584792148000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Catastrophic stroke burden in a patient with uncontrolled psoriasis and psoriatic arthritis: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Joline M.","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giselle Y.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey W.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene A.","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathra","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"key":"1681_CR1","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, et al. Prevalence and treatment of psoriasis in the United Kingdom. Arch Dermatol. 2005;141:1537.","journal-title":"Arch Dermatol"},{"key":"1681_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","volume":"60","author":"SK Kurd","year":"2009","unstructured":"Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218\u201324.","journal-title":"J Am Acad Dermatol"},{"key":"1681_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1759720X15591801","volume":"7","author":"L Eder","year":"2015","unstructured":"Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7:187\u201395.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1681_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/acr.23094","volume":"69","author":"K Jafri","year":"2017","unstructured":"Jafri K, et al. The incidence and Management of Cardiovascular Risk Factors in psoriatic arthritis and rheumatoid arthritis: a population-based study HHS public access. Arthritis Care Res. 2017;69:51\u20137.","journal-title":"Arthritis Care Res"},{"key":"1681_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1681_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1136\/ard.2008.094839","volume":"68","author":"DD Gladman","year":"2009","unstructured":"Gladman DD, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1681_CR7","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","volume":"129","author":"JM Gelfand","year":"2009","unstructured":"Gelfand JM, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411. https:\/\/doi.org\/10.1038\/jid.2009.112.","journal-title":"J Invest Dermatol"},{"key":"1681_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/01.CIR.89.5.2462","volume":"89","author":"HC Stary","year":"1994","unstructured":"Stary HC, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation. 1994;89:2462\u201378.","journal-title":"Circulation"},{"key":"1681_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1741-7015-12-47","volume":"12","author":"E Matsuura","year":"2014","unstructured":"Matsuura E, et al. Is atherosclerosis an autoimmune disease? BMC Med. 2014;12:47.","journal-title":"BMC Med"},{"key":"1681_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115\u201326.","journal-title":"N Engl J Med"},{"key":"1681_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685\u201395.","journal-title":"N Engl J Med"},{"key":"1681_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/annrheumdis-2012-201497","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013;72:715\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1681_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.22884","volume":"57","author":"C Gonzalez-juanatey","year":"2007","unstructured":"Gonzalez-juanatey C, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:1074\u201380.","journal-title":"Arthritis Rheum"},{"key":"1681_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/art.22530","volume":"57","author":"C Gonzalez-Juanatey","year":"2007","unstructured":"Gonzalez-Juanatey C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:287\u201393.","journal-title":"Arthritis Rheum"},{"key":"1681_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","volume":"147","author":"TJ Love","year":"2011","unstructured":"Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis. Arch Dermatol. 2011;147:419.","journal-title":"Arch Dermatol"},{"key":"1681_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1365-2133.2007.07986.x","volume":"157","author":"P Gisondi","year":"2007","unstructured":"Gisondi P, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case? Control study. Br J Dermatol. 2007;157:68\u201373.","journal-title":"Br J Dermatol"},{"key":"1681_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1365-2133.2008.08456.x","volume":"158","author":"Y Wang","year":"2008","unstructured":"Wang Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158:1134\u20135.","journal-title":"Br J Dermatol"},{"key":"1681_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","volume":"68","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68:654\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"1681_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2017.04.1133","volume":"77","author":"MJM Rodr\u00edguez-Z\u00fa\u00f1iga","year":"2017","unstructured":"Rodr\u00edguez-Z\u00fa\u00f1iga MJM, Garc\u00eda-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77:657\u2013666.e8.","journal-title":"J Am Acad Dermatol"},{"key":"1681_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"1681_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/bjd.12002","volume":"167","author":"T Xu","year":"2012","unstructured":"Xu T, Zhang Y-H. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol. 2012;167:1345\u201350.","journal-title":"Br J Dermatol"},{"key":"1681_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27","author":"C Horreau","year":"2013","unstructured":"Horreau C, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatology Venereol. 2013;27:12\u201329.","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"1681_CR23","doi-asserted-by":"publisher","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.","journal-title":"J Am Heart Assoc"},{"key":"1681_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2011.04.007","volume":"63","author":"AW Armstrong","year":"2011","unstructured":"Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci. 2011;63:1\u20139.","journal-title":"J Dermatol Sci"},{"key":"1681_CR25","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735.","journal-title":"JAMA"},{"key":"1681_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","volume":"13","author":"T Henseler","year":"1985","unstructured":"Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1681_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","volume":"52","author":"A Ogdie","year":"2013","unstructured":"Ogdie A, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology. 2013;52:568\u201375.","journal-title":"Rheumatology"},{"key":"1681_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/ijms19010058","volume":"19","author":"L Puig","year":"2017","unstructured":"Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19:58.","journal-title":"Int J Mol Sci"},{"key":"1681_CR29","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/acr.20627","volume":"63","author":"JA Husted","year":"2011","unstructured":"Husted JA, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. 2011;63:1729\u201335.","journal-title":"Arthritis Care Res"},{"issue":"2010","key":"1681_CR30","first-page":"e50","volume":"122","author":"P Greenland","year":"2010","unstructured":"Greenland P, et al. ACCF\/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the american college of cardiology foundation\/american heart association task force on practice guidelines. Circulation. 2010;122(2010):e50.","journal-title":"Circulation"},{"key":"1681_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2015.03.159","volume":"186","author":"G Kaiafa","year":"2015","unstructured":"Kaiafa G, et al. Is anemia a new cardiovascular risk factor? Int J Cardiol. 2015;186:117\u201324.","journal-title":"Int J Cardiol"},{"key":"1681_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11936-012-0173-x","volume":"14","author":"N Ali","year":"2012","unstructured":"Ali N, Srey R, Pavlakis S. Hemoglobinopathies and stroke: strategies for prevention and treatment. Curr Treat Options Cardiovasc Med. 2012;14:227\u201336.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"1681_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624.","journal-title":"Ann Rheum Dis"},{"key":"1681_CR34","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3389\/fimmu.2018.01668","volume":"9","author":"G Caiazzo","year":"2018","unstructured":"Caiazzo G, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668.","journal-title":"Front Immunol"},{"key":"1681_CR35","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173\u20137.","journal-title":"Lancet"},{"key":"1681_CR36","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/art.34335","volume":"64","author":"Y-J Chen","year":"2012","unstructured":"Chen Y-J, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum. 2012;64:1879\u201387.","journal-title":"Arthritis Rheum"},{"key":"1681_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jdv.12768","volume":"29","author":"O Ahlehoff","year":"2015","unstructured":"Ahlehoff O, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29:1128\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1681_CR38","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","volume":"165","author":"K Abuabara","year":"2011","unstructured":"Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165:1066\u201373.","journal-title":"Br J Dermatol"},{"issue":"26","key":"1681_CR39","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-020-01681-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01681-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T00:05:38Z","timestamp":1616285138000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01681-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01681-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,21]]},"assertion":[{"value":"2 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable; see consent for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the next of kin for the publication of this case report, patient images, and lab data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}